Imagene AI develops an AI-based genomic testing solution that utilizes histological data from cancer biopsies to inform personalized treatment strategies. This technology enables pharmaceutical companies and medical institutions to conduct precise molecular testing with minimal tissue samples, enhancing accessibility to tailored therapies for patients.
Funding
$21.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EGLEFounders
Product
Problem
Traditional molecular cancer testing methods often require extensive tissue samples and can have long turnaround times, delaying treatment decisions. This can lead to patient deterioration while waiting for results, hindering timely access to targeted therapies.
Solution
Imagene AI offers an AI-powered genomic testing solution that analyzes histological data from cancer biopsies to provide rapid, personalized treatment strategies. Their Oncology Intelligence Foundation Model decodes complex tissue patterns to provide actionable insights into disease mechanisms and tumor microenvironments. This enables pharmaceutical companies and medical institutions to conduct precise molecular testing with minimal tissue samples, enhancing accessibility to tailored therapies. The platform facilitates biomarker discovery to support drug development and advance precision medicine through a transformative SaaS enterprise solution utilizing AI to advance translational research and drive progress in drug development and clinical trials.
Target Audience
The primary customers are pharmaceutical companies, medical institutions, and clinical researchers involved in cancer research, drug development, and precision oncology.
Features
- AI-based analysis of histological data from cancer biopsies
- Rapid biomarker detection for faster treatment decisions
- Oncology Intelligence Foundation Model for diverse oncology applications
- Identification of disease mechanisms and tumor microenvironments
- Support for biomarker discovery and drug development
- Cloud-based platform accessible via Oracle Cloud Infrastructure